Option chain shows key data for Bioage Labs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bioage Labs.

Bioage Labs (NASDAQ:BIOA) Stock, Option Chain

Bioage Labs

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

Earnings

News

Futures

Previews

Events

Econ #s

Markets

Trading Ideas

ACRX

AERI

BIOA

CADE

CALM

CUDA

FSAM

NETS

ONCE

SAFM

TOCA

WDAY

ZKIN

The Week Ahead: New IPOs, Bank Earnings, And Some Notable FDA Actions

Eurozone

Commodities

Global

Intraday Update

CVGI

DEPO

EFII

FGEN

KOPN

KORS

Mid-Afternoon Market Update: Michael Kors Gains On Earnings Beat; Commercial Vehicle Shares Slide

Movers & Shakers

Analyst Ratings

Movers

AIRG

ATKR

CORE

ENDP

GWPH

HSNI

PAGP

PDCE

QTNT

QVCA

SYKE

22 Biggest Mid-Day Losers For Tuesday

Bioage Labs Inc

BIOASIS TECHNOLOGIES INC by Bioasis Technologies Inc.

Bioasis Technologies Inc

BIOADAPTIVES INC by Bioadaptives, Inc.

BIOADAPTIVES INC NEW by Bioadaptives, Inc.

BioAdaptives Inc

BioArctic AB

BioAtla Inc

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies Inc

WIIM

BioAge Labs shares are trading higher after the company announced it will present new preclinical data for its lead product candidate Azelapragor at ObesityWeek 2024.

Biotech

General

BioAge Labs To Present New Preclinical Data For Lead Product Candidate Azelapragor At ObesityWeek 2024

CORRECTION: Bioage Labs Ticker Is "BIOA"

BioAge Labs shares are trading higher after multiple firms initiated coverage on the stock with Buy ratings.

Citigroup analyst Samantha Semenkow initiates coverage on Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) with a Buy rating and announces Price Target of $45.

Price Target

Initiation

Citigroup Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $45

Morgan Stanley analyst Jeffrey Hung initiates coverage on Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) with a Overweight rating and announces Price Target of $40.

Morgan Stanley Initiates Coverage On Bioage Labs with Overweight Rating, Announces Price Target of $40

Jefferies analyst Roger Song initiates coverage on Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) with a Buy rating and announces Price Target of $42.

Jefferies Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $42

IPOs

Bioage Labs Shares Open For Trade At $22.50/Share; IPO Priced At $18/Share On 11M Shares

Bioage Labs IPO Indicating $34.97/Share On 102,099 Shares; IPO Priced At $18/Share On 11M Shares

Bioage Labs IPO Indicating $36/Share On 86,773 Shares; IPO Priced At $18/Share On 11M Shares

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Offerings

Reported Earlier, BioAge Labs Announced The Pricing Of Its Upsized Initial Public Offering Of 11M Shares Of Its Common Stock At A Public Offering Price Of $18.00 Per Share

BioAge Labs, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) IPO will take place September, 26 on the NASDAQ exchange under the ticker BIOA.
The company is offering shares at an expected price between $17.00 and $19.00 per share with an insider lock-up period of 180 days ending on March 25, 2025.
See also: <a href="https://www.benzinga.com/calendars/ipos">Benzinga IPO Calendar</a>
<h3>About BioAge Labs, Inc</h3>
BioAge Labs, Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging
See also: <a href="https://www.benzinga.com/short-interest">Benzinga's Most Shorted Stocks</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bioage Labs, Inc IPOs Tomorrow, Here's What You Need To Know

Analyst Color

H.C. Wainwright Place BioAmber 'Buy' Rating Under Review As A Petition For Relief Under Chapter 11 Was Filed

BioAmber Shares Down 4.8%; Earlier Co. Received Delisting Notice From Toronto Stock Exchange, Trading OTC Now

Hedge Funds

Earlier 13G Filing Shows Sabby Management Reporting 8.41% Stake In BioAmber

BioAmber Shares Down 9.8%, Continuing To Drop Following Tuesday's Delisting Notice From Toronto Stock Exchange

BioAmber Receives Deslisting Notice From Toronto Stock Exchange

&nbsp;BioAmber Inc. (NYSE:<a class="ticker" href="/stock/BIOA#NYSE">BIOA</a>) (TSX:<a class="ticker" href="/stock/BIOA#TSX">BIOA</a>) (&quot;BioAmber&quot; or the &quot;Company&quot;), announced today that it has entered into definitive agreements with certain institutional investors to purchase an aggregate of 46.67 million Series A units (or equivalent Series B Units), with each Series A unit consisting of one share of common stock, one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock, and each Series B unit consisting of one pre-funded warrant to purchase one share of common stock, one Series A warrant to purchase one share of common stock, one Series B warrant to purchase one share of common stock and one Series C warrant to purchase shares of common stock (subject to adjustment), at a price to the purchasers of&nbsp;US$0.15&nbsp;per Series A unit and&nbsp;US$0.149&nbsp;per Series B unit. The Series A warrants have an exercise price of&nbsp;US$0.15&nbsp;and a term of six (6) months, exercisable upon the date of issuance. The Series B warrants have an exercise price of&nbsp;US$0.15&nbsp;and a term of five (5) years, exercisable upon the date of issuance. The pre-funded warrants have an exercise price of&nbsp;US$0.15&nbsp;per share, which will be pre-paid upon issuance, except for a nominal exercise price of&nbsp;US$0.001&nbsp;per share and, consequently, no additional payment or other consideration (other than the nominal exercise price of&nbsp;US$0.001&nbsp;per share) will be required to be delivered to the Company by the holder upon exercise of the pre-funded warrants. The Series C warrants have a nominal exercise price of&nbsp;US$0.00001&nbsp;per share and, consequently, no additional payment or other consideration (other than the nominal exercise price of&nbsp;US$0.00001&nbsp;per share) will be required to be delivered to the Company by the holder upon exercise of the Series C warrants. The pre-funded warrants and the Series C warrants will be exercisable upon the date of issuance until exercised in full. The shares of common stock and the warrants will be immediately separable and will be issued separately. The number of shares underlying the Series C warrants is initially zero, but may be increased at the end of the 5th trading day following the public announcement of this offering (or such earlier trading day on which&nbsp;90%&nbsp;of our daily volume weighted average price of the Company&#39;s common stock on the Company&#39;s trading market on such date is equal to or less than&nbsp;$0.05), to an amount equal to the difference between (1) subscription amount of each purchaser of the Series A or B units divided by the lesser of (a) the original per-unit purchase price of the Series A or B units and (b) the greater of (i)&nbsp;90%&nbsp;of the lowest daily volume weighted average price of the Company&#39;s common stock on the Company&#39;s trading market during the five trading days including and immediately prior to such date and (ii)&nbsp;$0.05, and (2) the sum of the number of shares of common stock and pre-funded warrants, if any, issued to the purchaser at the closing of this offering. The per-share exercise prices of the Series A warrants and the Series B warrants may be decreased (but not increased) at the end of the 5th trading day following the public announcement of this offering (the &quot;Trigger Date&quot;), to an amount equal to the lesser of (a) the then exercise price, as adjusted, and (b) the greater of (i)&nbsp;90%of the lowest daily volume weighted average price of the Company&#39;s common stock on the Company&#39;s trading market during the five trading days including and immediately prior to such date and (ii)&nbsp;$0.05, and the number of shares issuable under the Series A warrants and Series B warrants will be increased such that the aggregate exercise price payable thereunder, after taking into account the adjusted exercise price, will be equal to the aggregate exercise price prior to the Trigger Date. In addition, if at any time while any of the warrants are still outstanding, the Company issues common stock or any type of securities giving the holders thereof the right to purchase common stock at a price below the purchase price (as adjusted) of the pre-funded warrants or the exercise price of the Series A warrants and the Series B warrants, the purchasers will have full-ratchet anti-dilution protection on any outstanding pre-funded warrants (via an increase in the number of shares of common stock underlying the pre-funded warrants) and the Series A warrants and Series B warrants (via a decrease in the exercise price per share thereof), subject to a&nbsp;$0.05&nbsp;floor. The aggregate gross proceeds to the Company (assuming no exercise of the warrants) are approximately&nbsp;US$7.0 million, before deducting placement agent fees and estimated offering expenses. H.C. Wainwright &amp; Co. is acting as the exclusive placement agent in connection with this offering. The closing of the offering is subject to customary closing conditions, and the quotation of the Company&#39;s common stock on a&nbsp;United States&nbsp;trading market, including the OTCBB, the OTCQB or the Pink Sheets. The closing of the offering is expected to occur two trading days following the quotation of the Company&#39;s common stock on one or more of such trading markets. The Company intends to use the net proceeds of the offering for working capital and general corporate purposes. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities described above are being offered by the Company pursuant to a &quot;shelf&quot; registration statement (File No. 333-215408) previously filed with the Securities and Exchange Commission (the &quot;SEC&quot;) on&nbsp;January 3, 2017&nbsp;and declared effective by the SEC on&nbsp;January 12, 2017. The offering may be made only by means of a prospectus supplement and the accompanying prospectus. A final prospectus supplement and the accompanying prospectus will be filed with the SEC and once filed, copies can be obtained by contacting H.C. Wainwright &amp; Co., LLC, 430 Park Avenue,&nbsp;New York, NY&nbsp;10022, by telephone 646-975-6996 or by email at&nbsp;<a href="mailto:placements@hcwco.com">placements@hcwco.com</a>&nbsp;or at the SEC&#39;s website at&nbsp;<a href="http://www.sec.gov/">http://www.sec.gov</a>. The Company will not be seeking the approval of the TSX in connection with this offering and it is expected that, as a result, the Company&#39;s common stock may be delisted from the TSX. The Company also announced that the underwriting agreement for its underwritten public offering that priced on&nbsp;February 6, 2018&nbsp;has been terminated by the Company&#39;s underwriter for this offering, due to the suspension and potential delisting of the Company&#39;s common stock from the NYSE. As a result of the termination of the underwriting agreement, no shares of common stock or warrants to purchase common stock will be issued in the underwritten public offering.

Press Releases

TSX:BIOA

BioAmber Inc. Announces Registered Direct Offering; Termination of Underwriting Agreement for Previously-Announced Public Offering; Will Purchase 46.67M Series A Units

BioAmber Reports 46.67M Series A Units Registered Direct Offering

Regeneron co-founder warns of harms from weight-loss drugs: FT

Weight loss drugs have one big issue; These companies want to fix it

Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies – Springview, Oriental Rise, PTL, Samfine C...

Opening Day: Self-driving startup Pony.ai files for U.S. IPO

Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group -- saw their stocks open for trading.

Self-Driving Startup Pony.ai Files For U.S. IPO

BioAge Labs, Inc. (BIOA) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung's rating is based on severa...

BioAge Labs, Inc.: Promising Developments and Strategic Partnerships Lead to Buy Rating

Jefferies initiated coverage of BioAge Labs (BIOA) with a Buy rating and $42 price target BioAge is a clinical stage biotech focusing on metabolic ...

BioAge Labs initiated with a Buy at Jefferies

Goldman Sachs initiated coverage of BioAge Labs (BIOA) with a Not Rated. The firm models for peak azelaprag sales of $8.5B in 2036 via peak penetra...

BioAge Labs intiated with a Not Rated at Goldman Sachs

Morgan Stanley initiated coverage of BioAge Labs (BIOA) with an Overweight rating and $40 price target Initial data for the company's azelaprag "ha...

BioAge Labs initiated with an Overweight at Morgan Stanley

Citi analyst Samantha Semenkow initiated coverage of BioAge Labs (BIOA) with a Buy rating and $45 price target BioAge is a clinical-staged biotech ...

BioAge Labs initiated with a Buy at Citi

BioAge Labs, Inc. ( ($BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors. Bi...

BioAge Labs Reports Strong Q3 2024 Achievements

BHVN

GRDN

KROS

LGCY

NONOF

ORIS

PTLE

REGN

SFHG

SPHL

SRRK

VERU

Contracts

BioArctic's partner Eisai presents updated sales simulation for Leqembi® at its annual press conference

Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed

BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm

BioAge Labs Announces Pricing of Upsized Initial Public Offering

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

BioAge Labs to Present at Jefferies London Healthcare Conference

Health Care

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

BrainTransporter™ dramatically improves antibody delivery to the brain

Management

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

Comments

Bioage Labs

Bioage Labs (BIOA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga